A Phase 3 trial of a lipid-lowering drug involving more than 13,000 patients has been discontinued after the study’s monitors concluded the medicine was unlikely to deliver benefits to patients. The sponsor, AstraZeneca Plc, was attempting to show that patients with mixed dyslipidaemia who are at risk of cardiovascular disease could be helped by Epanova (omega-3 carboxylic acids), a compound derived from fish oil. The patients were all on optimal statin therapy. But the independent data monitoring committee concluded that a benefit was unlikely.
